Preclinical News and Research

RSS

First compound for receptors in schizophrenia and Alzheimer's holds promise

For almost 20 years, pharmacological companies have known that certain compounds that activate two specific CNS receptors, causing them to release the neurotransmitter acetylcholine, are effective in treating the cognitive and motor problems related to both schizophrenia and Alzheimer's disease (AD).

20 Apr 2009

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center.

20 Apr 2009

Chemists synthesize natural alkaloid that could have anti-cancer properties

The club moss Lycopodium serratum is a creeping, flowerless plant used in homeopathic medicine to treat a wide variety of ailments.

15 Apr 2009

$Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma$

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

13 Apr 2009

Experimental drug lowers PSA levels

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed.

9 Apr 2009

Intercell starts trial for Streptococcus pneumoniae vaccine candidate

Intercell AG has announced that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has started.

8 Apr 2009

Stem cells from bone marrow used to grow new blood vessels

Research led by David Hess of the Robarts Research Institute at The University of Western Ontario has identified how to use selected stem cells from bone marrow to grow new blood vessels to treat diseases such as peripheral artery disease.

6 Apr 2009

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

AVEO Pharmaceuticals, Inc. has announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop over time in mice and mimic human tumor behaviors and response.

6 Apr 2009

Nanobiotix reports 'proof of concept' for use of nanoparticles in treating glioblastoma multiforme

Nanobiotix has announced that an independent preclinical study has validated the applicability of using its nanoparticles-nanoPDT-to treat glioblastoma multiforme, one of the most prevalent brain tumors. Nanobiotix expects to attract corporate partners for the development of nanoPDT as the Company focuses development efforts on its nanoXray technology.

6 Apr 2009

FDA provides positive review of InNexus Biotechnology development plan for lead preclinical candidate

InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).

2 Apr 2009

FDA clears Cellectar's IND application for drug candidate

Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.

2 Apr 2009

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

CeNeRx BioPharma, Inc. has announced issuance of a new U.S. patent covering its novel compounds that selectively target peripheral cannabinoid receptors.

1 Apr 2009

Researchers develop mouse models of leukemia that predict response to chemotherapy

Being able to accurately predict how a given cancer will respond to chemotherapy would spare patients with non-responsive tumors the burden of undergoing toxic and ultimately unhelpful treatment.

1 Apr 2009

By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies

Researchers at Georgetown University Medical Center (GUMC) have been able to speed recovery and substantially reduce damage resulting from spinal cord injury in preclinical studies.

1 Apr 2009

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.

30 Mar 2009

Intercell receives FDA approval of IXIARO, novel vaccine for Japanese encephalitis

Intercell AG (VSE: ICLL) today announced that the U.S. Food and Drug Administration (FDA) approved IXIARO(R), a new vaccine for the prevention of Japanese Encephalitis (JE).

30 Mar 2009

Missing enzyme GNSOR conveys major heart protection in pre-clinical work

Mice born without a certain enzyme can resist the normal effects of a heart attack and retain nearly normal function in the heart's ventricles and still-oxygenated heart tissue, according to a study by researchers at Duke University Medical Center.

30 Mar 2009

Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

Radius Health ("Radius") announced today that the first patient has been dosed in the company's proof-of-concept Phase 2a study of RAD1901, an investigational selective estrogen receptor modulator (SERM) undergoing clinical evaluation for treatment of vasomotor symptoms (menopausal hot flashes).

24 Mar 2009

Orexo reports on efficacy study in allergic rhinitis with OX914

Orexo has reported clinical results from an experimental phase IIa safety and efficacy study in allergic rhinitis with OX914, the first compound in its Phosphodiesterase 4 (PDE4) inhibitor program.

24 Mar 2009

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase II clinical trial of cicletanine hydrochloride (cicletanine), an oral agent in development for the treatment of pulmonary arterial hypertension (PAH).

24 Mar 2009

Preclinical News and Research

First compound for receptors in schizophrenia and Alzheimer's holds promise

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

Chemists synthesize natural alkaloid that could have anti-cancer properties

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Experimental drug lowers PSA levels

Intercell starts trial for Streptococcus pneumoniae vaccine candidate

Stem cells from bone marrow used to grow new blood vessels

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

Nanobiotix reports 'proof of concept' for use of nanoparticles in treating glioblastoma multiforme

FDA provides positive review of InNexus Biotechnology development plan for lead preclinical candidate

FDA clears Cellectar's IND application for drug candidate

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

Researchers develop mouse models of leukemia that predict response to chemotherapy

By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

Intercell receives FDA approval of IXIARO, novel vaccine for Japanese encephalitis

Missing enzyme GNSOR conveys major heart protection in pre-clinical work

Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

Orexo reports on efficacy study in allergic rhinitis with OX914

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics